KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Current Assets (2016 - 2025)

Vertex Pharmaceuticals has reported Current Assets over the past 17 years, most recently at $11.2 billion for Q4 2025.

  • Quarterly results put Current Assets at $11.2 billion for Q4 2025, up 16.72% from a year ago — trailing twelve months through Dec 2025 was $11.2 billion (up 16.72% YoY), and the annual figure for FY2025 was $11.2 billion, up 16.72%.
  • Current Assets for Q4 2025 was $11.2 billion at Vertex Pharmaceuticals, up from $10.6 billion in the prior quarter.
  • Over the last five years, Current Assets for VRTX hit a ceiling of $14.7 billion in Q3 2023 and a floor of $8.5 billion in Q2 2021.
  • Median Current Assets over the past 5 years was $10.5 billion (2025), compared with a mean of $11.1 billion.
  • Biggest five-year swings in Current Assets: soared 56.79% in 2021 and later crashed 35.55% in 2024.
  • Vertex Pharmaceuticals' Current Assets stood at $9.6 billion in 2021, then surged by 38.43% to $13.2 billion in 2022, then increased by 6.87% to $14.1 billion in 2023, then crashed by 32.15% to $9.6 billion in 2024, then increased by 16.72% to $11.2 billion in 2025.
  • The last three reported values for Current Assets were $11.2 billion (Q4 2025), $10.6 billion (Q3 2025), and $10.4 billion (Q2 2025) per Business Quant data.